67Ga-SPECT/CT with a hybrid system in the clinical management of lymphoma

  • Barbara Palumbo
  • Silvio Sivolella
  • Isabella Palumbo
  • Anna Marina Liberati
  • Renato Palumbo
Original Article

Abstract

Purpose

The purpose of this study was to investigate the added value of co-registered fusion imaging using a hybrid system in patients with lymphoma.

Methods

Twenty-four lymphoma patients underwent 67Ga-SPECT/CT using a hybrid tomograph consisting of a dual-head, variable-angle gamma camera and a low-dose X-ray tube. Results were compared with those of SPECT alone.

Results

Forty-five lesions were identified by SPECT alone, while 49 were detected by SPECT/CT. Forty out of the 45 lesions observed on SPECT were confirmed as lymphoma, but five were due to other causes (thoracic aorta blood pool activity, sialoadenitis in the submandibular gland, bowel activity, rib fracture and bone marrow activation due to radiotherapy). SPECT/CT identified nine more neoplastic lesions compared with SPECT alone: four areas of radiopharmaceutical accumulation were observed in para-aortic lymph nodes, three in the spleen, one in the liver and one in para-iliac lymph nodes. In five cases, SPECT/CT provided additional anatomical information over SPECT alone. In four patients, four large areas of 67Ga uptake (one mediastinal, two supraclavicular and one para-aortic) were better characterised; in one subject uptake was localised in the seventh thoracic vertebra only by SPECT/CT. Hybrid imaging provided additional data in 13 patients (54.2%), thus inducing oncologists to reconsider the therapeutic approach in eight subjects (33.2%): unnecessary treatment was avoided in four (16.6%) while therapy was altered in another four (16.6%).

Conclusion

SPECT/CT hybrid system is able to provide information not obtained by SPECT alone. It allows the anatomical localisation of lymphoma and physiological radiopharmaceutical uptake, facilitates the diagnosis of tumours located in the abdomen (subdiaphragmatic lesions) and provides information that may cause a change in therapeutic strategy.

Keywords

Lymphoma Gallium-67 scintigraphy Hybrid imaging system SPECT/CT 

References

  1. 1.
    Vinnicombe SJ, Reznek RH. Computerized tomography in the staging of Hodgkin’s disease and non-Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 2003;30 Suppl 1:S42–55PubMedGoogle Scholar
  2. 2.
    Rankin SC. Assessment of response to therapy using conventional imaging. Eur J Nucl Med Mol Imaging 2003;30 Suppl 1:S56–64PubMedGoogle Scholar
  3. 3.
    Sapir EE, Israel O. Gallium-67 scintigraphy: a cornerstone in functional imaging of lymphoma. Eur J Nucl Med Mol Imaging 2003;30 Suppl 1:S65–81PubMedGoogle Scholar
  4. 4.
    Castellani MR, Cefalo G, Terenziani M, Aliberti G, Maccauro M, Alessi A, et al. Gallium scan in adolescents and children with Hodgkin’s disease (HD): treatment response assessment and prognostic value. Q J Nucl Med 2003;47(1):22–30PubMedGoogle Scholar
  5. 5.
    Front D, Bar-Shalom R, Mor M, Haim N, Epelbaum R, Frenkel A, et al. Hodgkin disease: prediction of outcome with 67Ga scintigraphy after one cycle of chemotherapy. Radiology 1999;210:487–91PubMedGoogle Scholar
  6. 6.
    Front D, Bar-Shalom R, Mor M, Haim N, Epelbaum R, Frenkel A, et al. Aggressive non-Hodgkin lymphoma: early prediction of outcome with 67Ga scintigraphy. Radiology 2000;214:253–7PubMedGoogle Scholar
  7. 7.
    Bar-Shalom R, Mor M, Yefremov N, Goldsmith SJ. The value of Ga-67 scintigraphy and F-18 fluorodeoxyglucose positron emission tomography in staging and monitoring the response of lymphoma to treatment. Semin Nucl Med 2001;31:177–90PubMedGoogle Scholar
  8. 8.
    Kostakoglu L, Goldsmith SJ. Positron emission tomography in lymphoma: comparison with computed tomography and gallium-67 single photon emission computed tomography. Clin Lymphoma 2000;1:67–74PubMedGoogle Scholar
  9. 9.
    Chajari M, Lacroix J, Peny AM, Chesnay E, Batalla A, Henry-Amar M, et al. Gallium-67 scintigraphy in lymphoma: is there a benefit of image fusion with computed tomography? Eur J Nucl Med Mol Imaging 2002;29:380–7CrossRefPubMedGoogle Scholar
  10. 10.
    Keidar Z, Israel O, Krausz Y. SPECT/CT in tumour imaging: technical aspects and clinical applications. Semin Nucl Med 2003;33 3:205–18CrossRefPubMedGoogle Scholar
  11. 11.
    Israel O, Yefremov N, Mor M, Haim N, Gaitini D, Epelbaum R, et al. A new technology of combined transmission (CT) and emission (67Ga) tomography (TET) in the evaluations of patients with lymphoma (abstract). J Nucl Med 2000;41:70pGoogle Scholar
  12. 12.
    Israel O, Yefremov N, Mor M, Epelbaum R, Dann EJ, Gaitini D, et al. Combined transmission (CT) and Ga-67 emission tomography (TET) in the evaluation of response to treatment and diagnosis of recurrence in patients with lymphoma (abstract). Eur J Nucl Med 2000;27:1160Google Scholar
  13. 13.
    Sivolella S, Palumbo B, Palumbo I, Liberati AM, Moschini TO, Fiorucci G, et al. Usefulness of SPECT/CT with Ga-67 in evaluating patients with lymphoma (abstract). Q J Nucl Med Mol Imaging 2004;48(1):34Google Scholar
  14. 14.
    Bombardieri E, Aktolun C, Baum RP, Bishof-Delaloye A, Buscombe J, Chatal JF, et al. 67Ga scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 2003;30(12):BP125–31PubMedGoogle Scholar
  15. 15.
    Schillaci O, Danieli R, Manni C, Simonetti G. Is SPECT/CT with a hybrid camera useful to improve scintigraphic imaging interpretation? Nucl Med Commun 2004;25(7):705–10CrossRefPubMedGoogle Scholar
  16. 16.
    Schillaci O. Functional–anatomical image fusion in neuroendocrine tumors. Cancer Biother Radiopharm 2004;19(1):129–34CrossRefPubMedGoogle Scholar
  17. 17.
    Schillaci O, Danieli R, Manni C, Capoccetti F, Simonetti G. Technetium-99m-labelled red blood cell imaging in the diagnosis of hepatic haemangiomas: the role of SPECT/CT with a hybrid camera. Eur J Nucl Med Mol Imaging 2004;31:1011–5CrossRefPubMedGoogle Scholar
  18. 18.
    Tharp K, Israel O, Hausmann J, Bettman L, Martin WH, Daitzchman M, et al. Impact of 131I-SPECT/CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma. Eur J Nucl Med Mol Imaging 2004;31:1435–42CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Barbara Palumbo
    • 1
  • Silvio Sivolella
    • 1
  • Isabella Palumbo
    • 2
  • Anna Marina Liberati
    • 2
  • Renato Palumbo
    • 1
  1. 1.Nuclear Medicine Section, Department of Radiological SciencesUniversity of PerugiaPerugiaItaly
  2. 2.Internal Medicine and Oncology, Department of Clinical and Experimental MedicineUniversity of PerugiaPerugiaItaly

Personalised recommendations